Contemporary classification of histiocytic disorders

BE Favara, AC Feller, M Pauli, ES Jaffe… - … : The Official Journal …, 1997 - Wiley Online Library
Pathologists and pediatric hematologist/oncologists of the World Health Organization's
Committee on Histiocytic/Reticulum Cell Proliferations and the Reclassification Working …

Histopathology and immunohistochemistry of peripheral T cell lymphomas: a proposal for their classification.

T Suchi, K Lennert, LY Tu, M Kikuchi, E Sato… - Journal of clinical …, 1987 - jcp.bmj.com
Based on the results of histological and immunohistochemical observations of a large
number of peripheral T cell lymphomas from China, England, Germany and Japan …

Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene

B Sadlack, H Merz, H Schorle, A Schimpl, AC Feller… - Cell, 1993 - cell.com
Mice deficient for interleukin-2 develop normally during the first 3-4 weeks of age. However,
later on they become severely compromised, and about 50% of the animals die between 4 …

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial …

M Pfreundschuh, J Schubert, M Ziepert… - The lancet …, 2008 - thelancet.com
Background Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is used
to treat patients with non-Hodgkin lymphoma. Interval decrease from 3 weeks of treatment …

[HTML][HTML] A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling

M Hummel, S Bentink, H Berger… - … England Journal of …, 2006 - Mass Medical Soc
Background The distinction between Burkitt's lymphoma and diffuse large-B-cell lymphoma
is unclear. We used transcriptional and genomic profiling to define Burkitt's lymphoma more …

Immunohistological analysis of human lymphoma: correlation of histological and immunological categories

H Stein, K Lennert, AC Feller, DY Mason - Advances in cancer research, 1984 - Elsevier
Publisher Summary The analysis of human tissue lymphoma biopsies by
immunohistological techniques provides the opportunity for investigating whether previously …

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of …

M Pfreundschuh, L Trümper, M Kloess, R Schmits… - Blood, 2004 - ashpublications.org
Cyclophosphamide, doxorubicin, vincristine, and prednisone, given every 3 weeks (CHOP-
21), is standard chemotherapy for aggressive lymphomas. To determine whether biweekly …

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a …

A Pastore, V Jurinovic, R Kridel, E Hoster… - The lancet …, 2015 - thelancet.com
Background Follicular lymphoma is a clinically and genetically heterogeneous disease, but
the prognostic value of somatic mutations has not been systematically assessed. We aimed …

Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas: definitions, differential diagnosis, and epidemiology

ES Jaffe, JKC Chan, IJ Su, G Frizzera… - The American journal …, 1996 - journals.lww.com
A workshop jointly sponsored by the University of Hong Kong and the Society for
Hematopathology explored the definition, differential diagnosis, and epidemiology of …

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma

H Horn, M Ziepert, C Becher, TFE Barth… - Blood, The Journal …, 2013 - ashpublications.org
MYC rearrangements occur in 5% to 10% of diffuse large B-cell lymphomas (DLBCL) and
confer an increased risk to cyclophosphamide, hydroxydaunorubicin, oncovin, and …